Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionCommonwealth Equity Services, Llc
Latest Disclosed Ownership14,501 shares
Latest Disclosed Value $ 2,056,680
Commonwealth Equity Services, Llc reports 1.24% increase in ownership of NBIX / Neurocrine Biosciences, Inc.

On February 12, 2026 - Commonwealth Equity Services, Llc filed a 13F-HR form disclosing ownership of 14,501 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $2,056,680 USD as of December 31, 2025. The entity filed a previous 13F-HR on October 22, 2025 disclosing 14,323 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 1.24% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-12 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,501 178 1.24 2,057 102,700.00 0.0027
2025-10-22 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,323 222 1.57 2 100.00 0.0026
2025-08-06 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,101 390 2.84 2 0.00 0.0023
2025-05-09 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 13,711 -245 -1.76 2 0.00 0.0021
2025-02-10 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 13,956 -1,320 -8.64 2 0.00 0.0028
2024-10-18 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,276 360 2.41 2 -50.00 0.0027
2024-07-31 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,916 975 6.99 2 100.00 0.0033
2024-04-29 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 13,941 84 0.61 2 0.00 0.0032
2024-02-06 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 13,857 -150 -1.07 2 0.00 0.0033
2023-10-23 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,007 -1,097 -7.26 2 0.00 0.0033
2023-08-10 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,104 -234 -1.53 1 0.00 0.0029
2023-05-11 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,338 200 1.32 2 0.00 0.0033
2023-02-07 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,138 440 2.99 2 -99.94 0.0043
2022-11-14 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,698 -1,809 -10.96 1,561 -2.98 0.0040
2022-07-19 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 16,507 -2,138 -11.47 1,609 -7.95 0.0042
2022-05-04 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 18,645 182 0.99 1,748 11.20 0.0040
2022-01-31 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 18,463 -342 -1.82 1,572 -12.81 0.0035
2021-10-29 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 18,805 -1,375 -6.81 1,803 -8.15 0.0045
2021-08-11 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 20,180 537 2.73 1,963 2.77 0.0050
2021-05-04 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 19,643 -1,221 -5.85 1,910 -4.45 0.0054
2021-02-11 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 20,864 -3,278 -13.58 1,999 -13.87 0.0060
2020-11-05 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 24,142 217 0.91 2,321 -20.46 0.0079
2020-08-12 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 23,925 705 3.04 2,918 45.25 0.0110
2020-05-11 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 23,220 265 1.15 2,009 -18.57 0.0094
2020-02-05 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 22,955 8,721 61.27 2,467 92.43 0.0094
2019-10-30 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,234 -232 -1.60 1,282 5.00 0.0055
2019-07-19 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,466 -576 -3.83 1,221 -7.85 0.0054
2019-05-13 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,042 4,665 44.96 1,325 78.81 0.0061
2019-02-11 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 10,377 -681 -6.16 741 -45.47 0.0039
2018-11-06 2018-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 11,058 8,989 434.46 1,359 569.46 0.0065
2018-07-31 2018-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,069 2,069 203 0.0011
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.